Economic evaluation of the effect of needle and syringe programs on skin, soft tissue, and vascular infections in people who inject drugs: a microsimulation modelling approach

Table 4 Estimates of cost, QALY, and ICER with and without NSP

Scenario	Intervention	Cost	MCSE	QALY	MCSE	INC Cost	MCSE	INC QALY	MCSE	ICER
Base Case	No NSP	$919	14	3.939	0.003
Base Case	NSP	$2125	12	3.956	0.003	$1207	7	0.017	0.001	$70,278/QALY
Discount Rate 0%	No NSP	$945	14	4.052	0.003
Discount Rate 0%	NSP	$2187	13	4.07	0.003	$1241	7	0.018	0.001	$69,455/QALY
Discount Rate 3%	No NSP	$894	14	3.832	0.003
Discount Rate 3%	NSP	$2068	12	3.849	0.003	$1174	7	0.017	0.001	$71,108/QALY
Annual NSP Cost^a ($300)	No NSP	$919	14	3.939	0.003
Annual NSP Cost^a ($300)	NSP	$2019	12	3.956	0.003	$1100	7	0.017	0.001	$64,103/QALY
Annual NSP Cost^a ($350)	No NSP	$919	14	3.939	0.003
Annual NSP Cost^a ($350)	NSP	$2262	12	3.956	0.003	$1343	7	0.017	0.001	$78,218/QALY
Annual NSP Cost^a ($375)	No NSP	$919	14	3.939	0.003
Annual NSP Cost^a ($375)	NSP	$2383	12	3.956	0.003	$1464	7	0.017	0.001	$85,276/QALY
Annual NSP Cost^a ($400)	No NSP	$919	14	3.939	0.003
Annual NSP Cost^a ($400)	NSP	$2504	12	3.956	0.003	$1585	7	0.017	0.001	$92,333/QALY

ICER incremental cost-effectiveness ratio, INC incremental, MCSE Monte Carlo standard error, NSP needle and syringe programs, QALY quality-adjusted life-years
^aNSP costs refer to the annual cost per person who injects drugs
Note: The results in this table were compiled using data from the © Government of Québec (Research file publication date: 2009–2019; Data use approval date: 20 September 2021)

ISSN: 1477-7517